The share price of the company climbed as much as 9.75 per cent to Rs 452.40, its 52-week high, on BSE.
Shares of Jubilant Life Sciences hit a new 52-week high on Tuesday after the company informed stock exchanges that it has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for its generic version of antidepressant Paxil tablets.
The share price of the company climbed as much as 9.75 per cent to Rs 452.40, its 52-week high, on BSE.
At 1.38 pm, the share price of Jubilant Life Sciences was up 8.55 per cent at Rs 452.85. The scrip opened at Rs 414 and had touched a high and low of Rs 452.40 and Rs 411.50, respectively, in trade so far.
In a release, the company said, “Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the USFDA for Paroxetine Tablets USP, 10 mg, 20 mg, 30 mg and 40 mg,
the generic version of Paxil Tablets, 10 mg, 20 mg, 30 mg, and 40 mg® (of Apotex), which is
used as an antidepressant.”
As on September 30, 2015, Jubilant Life Sciences had a total of 820 filings for formulations of
which 391 have been approved in various regions globally.
This includes 71 ANDAs filed in the US, of which 39 have been approved and 46 Dossier filings in Europe.
| Subscribe To Our Free Newsletter |
